Sep. 6, 2021
Nouryon, a global specialty chemicals leader, announced on September 3rd that Nouryon B.V., an affiliated entity that is expected to become the parent company of the Nouryon group, has confidentially submitted a draft registration statement on Form F-1 with the Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its ordinary shares.
The number of shares to be offered and the price range for the proposed offering have not yet been determined. Nouryon expects to use the proceeds of the offering for general corporate purposes, which may include the repayment of indebtedness. The initial public offering is expected to commence after the SEC completes its review process, subject to market and other conditions.
This media release is being made pursuant to, and in accordance with, Rule 135 under the Securities Act of 1933, as amended, and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.
To learn more advanced Formulation, Adjuvant and Application Technologies, pls click the picture below to download 2021 Formulation&Adjuvant Technology magazine.
If you'd like to share your company/product story, please contact Grace Yuan via: email@example.com
Click here to view more previous magazines.